NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Ernexa Therapeutics Inc. ERNA
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.24
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-686.7%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -2.24
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-686.7%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-253.7%
Each USD of equity lost 687 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−50.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−50.6%
−31.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+15.0%
Change, 10 years—
The share count grew 15% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.8M
total assets, end of FY2025
Total assetsUSD 5.8M
EquityUSD 2.4M
CashUSD 1.9M
Current ratio1.01×
Equity funds 41% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
Income tax $B
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.24
−48.96
−4.08
−8.06
−56.61
−0.41
−0.72
−0.10
−0.45
−1.54
−3.93
−0.06
−0.01
−0.01
−0.06
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−686.7
−2264.3
−302.2
−130.7
−739.1
−83.8
−24.6
−4.2
−22.4
−73.9
−97.8
−50.0
−12.3
−14.0
−43.2
−4.2
Shares out B
0.01
0.00
0.01
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.09
0.08
0.07
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
51 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed